Cargando…
The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
BACKGROUND: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a “reversal” effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668220/ https://www.ncbi.nlm.nih.gov/pubmed/38024523 http://dx.doi.org/10.4103/jrms.jrms_626_21 |
_version_ | 1785139417478856704 |
---|---|
author | Liu, Tao Zhou, Ping Jiang, Xin Wang, Na Shou, Jialing Fang, Yuqiang |
author_facet | Liu, Tao Zhou, Ping Jiang, Xin Wang, Na Shou, Jialing Fang, Yuqiang |
author_sort | Liu, Tao |
collection | PubMed |
description | BACKGROUND: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a “reversal” effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. MATERIALS AND METHODS: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of “complete reversal” included left ventricular end-diastolic diameter (LVEDD) ≤50 mm for females or ≤55 mm for males and left ventricular ejection fraction (LVEF) ≥45%; the criteria of “partial reversal” was the decreased rate of LVEDD (ΔLVEDD) >10% or the increase rate of LVEF (ΔLVEF) >10%; the criteria of “no reversal” included LVEDD >50 mm for females or >55 mm for males and ΔLVEDD <10%, and LVEF <45% and ΔLVEF <10%. RESULTS: Within the follow-up period, nine patients showed “complete reversal,” eight “partial reversal,” and nine “no reversal.” Improvements in echocardiogram parameters were the most significant in “complete reversal” patients (P < 0.001), followed by “partial reversal” and “no reversal” patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in “complete reversal” patients were the shortest, followed by “partial reversal” and “no reversal” patients. CONCLUSION: ACEIs or ARBs and BBs have a “complete reversal” effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response. |
format | Online Article Text |
id | pubmed-10668220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-106682202023-08-24 The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy Liu, Tao Zhou, Ping Jiang, Xin Wang, Na Shou, Jialing Fang, Yuqiang J Res Med Sci Original Article BACKGROUND: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a “reversal” effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. MATERIALS AND METHODS: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of “complete reversal” included left ventricular end-diastolic diameter (LVEDD) ≤50 mm for females or ≤55 mm for males and left ventricular ejection fraction (LVEF) ≥45%; the criteria of “partial reversal” was the decreased rate of LVEDD (ΔLVEDD) >10% or the increase rate of LVEF (ΔLVEF) >10%; the criteria of “no reversal” included LVEDD >50 mm for females or >55 mm for males and ΔLVEDD <10%, and LVEF <45% and ΔLVEF <10%. RESULTS: Within the follow-up period, nine patients showed “complete reversal,” eight “partial reversal,” and nine “no reversal.” Improvements in echocardiogram parameters were the most significant in “complete reversal” patients (P < 0.001), followed by “partial reversal” and “no reversal” patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in “complete reversal” patients were the shortest, followed by “partial reversal” and “no reversal” patients. CONCLUSION: ACEIs or ARBs and BBs have a “complete reversal” effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response. Wolters Kluwer - Medknow 2023-08-24 /pmc/articles/PMC10668220/ /pubmed/38024523 http://dx.doi.org/10.4103/jrms.jrms_626_21 Text en Copyright: © 2023 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Liu, Tao Zhou, Ping Jiang, Xin Wang, Na Shou, Jialing Fang, Yuqiang The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
title | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
title_full | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
title_fullStr | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
title_full_unstemmed | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
title_short | The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
title_sort | complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668220/ https://www.ncbi.nlm.nih.gov/pubmed/38024523 http://dx.doi.org/10.4103/jrms.jrms_626_21 |
work_keys_str_mv | AT liutao thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT zhouping thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT jiangxin thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT wangna thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT shoujialing thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT fangyuqiang thecompletereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT liutao completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT zhouping completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT jiangxin completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT wangna completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT shoujialing completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy AT fangyuqiang completereversaleffectfollowingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockersandbetablockersaftertheprimarydiagnosisofdilatedcardiomyopathy |